Physician profile
Tabatha Timberman
NPI 1033780473
$901.82
in general payments reported to CMS, 2019-2025
14 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.49 · 2022: $67.10 · 2023: $105 · 2024: $220 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.85 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $173.70 | 2022-2025 | Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $154.41 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $103.97 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $72.62 | 2024-2025 | Dupixent |
| Esperion Therapeutics, INC. | $71.49 | 2021 | |
| Amgen INC. | $69.67 | 2023-2025 | Tezspire |
| Grifols USA, LLC | $57.06 | 2024-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.35 | 2024-2025 | Ofev, Jascayd |
| Insmed, INC. | $38.78 | 2025 | Brinsupri, Arikayce |
| Viatris Specialty LLC | $37.68 | 2025 | Yupelri |
| Verona Pharma, INC. | $23.40 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $18.91 | 2024 | Yupelri |
| Electromed, INC. | $14.90 | 2025 | Smartvest |
| Inspire Medical Systems, INC. | $14.88 | 2023 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabatha Timberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.